I have talked a lot about our need to take the next step in clinical care, understanding the best sequencing of our drugs. Since we have a number of new drugs to treat advanced prostate cancer we now need to better understand which drugs should be used in which men as well as their proper [...]
Cancer is a genetic disease, so prostate cancer is a genetic problem. This statement might be the most important one we can make when trying to describe the current, overall situation we face as prostate cancer survivors! Many institutions have begun significant research studies trying to understand the actual genetic keys to prostate cancer. Prostate [...]
During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]
It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer. These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job [...]
According to Prostate Cancer UK The National Institute for Health and Care Excellence (NICE) has released its second draft decision on the availability of radium-223 (Xofigo). Different from the original draft this draft recommends that radium-223 be made available on the NHS for men with advanced prostate cancer that no longer responds to hormone therapy [...]